What is Wellumio?
Wellumio is a pioneering medical technology firm dedicated to transforming the landscape of acute stroke diagnostics. Its flagship product, Axana, represents a significant leap forward in portable brain imaging, specifically engineered to operate within the critical Golden Hour following a stroke. By utilizing AI-enhanced magnetic resonance imaging, the company effectively removes traditional infrastructure bottlenecks, allowing emergency medical services and healthcare facilities to perform high-fidelity diagnostics directly at the point of care. This decentralized approach to neuro-imaging is designed to drastically reduce time-to-treatment, thereby improving patient outcomes and optimizing healthcare resource allocation across global clinical environments.
How much funding has Wellumio raised?
Wellumio has raised a total of $14.1M across 2 funding rounds:
Seed
$4.3M
Other Financing Round
$9.8M
Seed (2023): $4.4M, investors not publicly disclosed
Other Financing Round (2026): $9.8M led by The NZGCP, Flying Kiwi Angels, Bioshore Ventures, Pacific Channel, Enterprise Angels, Icehouse Ventures, Booster, Nuance Capital, and Cure Kids
Key Investors in Wellumio
Bioshore Ventures
Bioshore Ventures is an investment firm focused on catalyzing medical innovation in Australia, leveraging its favorable R&D environment and strong healthcare infrastructure to drive successful clinical and commercial outcomes.
Pacific Channel
Pacific Channel is a leading Asia-Pacific funds management firm that specializes in deep-tech and alternative investments, focusing on delivering meaningful value and impact in the health and environmental sectors.
Nuance Capital
Nuance Capital Ltd is a deep-tech fund that connects exceptional entrepreneurs with global opportunities, focusing on advanced engineering, science, and AI solutions that address global challenges.
What's next for Wellumio?
With the recent infusion of capital, Wellumio is poised to transition into a phase of rapid commercial expansion and clinical validation. The strategic focus will likely shift toward scaling the manufacturing of the Axana platform and securing regulatory approvals in key international markets. By leveraging its strong backing from specialized deep-tech and medical-focused investment firms, Wellumio is expected to deepen its integration with emergency response networks. The company's roadmap suggests a concerted effort to establish Axana as the standard of care for mobile stroke diagnostics, ultimately aiming to reduce the long-term morbidity associated with neurological emergencies through faster, more accessible intervention.
See full Wellumio company page
